MOTS-c
A peptide encoded in your mitochondria, studied for cellular energy and metabolism, prescribed within a clinician-led plan built on your labs.
- Studied for insulin sensitivity and metabolic regulation
- Explored for cellular energy through the AMPK pathway
- Used to support a training, nutrition and sleep plan
Individual results vary. MOTS-c adds to training, nutrition and sleep; it does not replace them.
- Live visit with a licensed clinician
- If prescribed, medication is included in the price and delivered to your home
- Subscription, cancel anytime
Indicative price · confirmed after eligibility · prescription treatment
What MOTS-c is
MOTS-c is a short peptide, sixteen amino acids long, whose sequence is written inside mitochondrial DNA rather than the nuclear genome.
That is what made it a genuine scientific finding when a university research group described it in 2015. Mitochondria were understood to encode a small set of proteins for their own machinery and little else. A peptide encoded there that travels in the bloodstream and acts on distant tissue suggests the mitochondrion reporting its state to the rest of the body.
Circulating MOTS-c is measurable in human plasma, rises during exercise and has been reported to fall with age, which is why it has become a focus of metabolic and healthy-aging research.
At ACT 2, MOTS-c is prescribed by a licensed clinician within a metabolic plan built on your labs, prepared by a licensed U.S. compounding pharmacy, at a published monthly price with no membership fee.
MOTS-c is a peptide encoded in mitochondrial rather than nuclear DNA, a discovery that made it one of the most interesting molecules in metabolic research. It is studied for its role in insulin sensitivity, cellular energy and metabolic regulation, mostly in cell and animal work. It is not FDA-approved; it is prepared by a licensed compounding pharmacy under an individual prescription.
How it works here
Every plan follows one path. Each step feeds the next. See the Peptide Therapy approach.
- 01
Measure
We baseline your labs, history, and goals.
- 02
Plan
A clinician decides whether this fits — and what else might serve you.
- 03
Act
If appropriate, you start with clear guidance and high-touch support.
- 04
Track
We monitor how you respond on a defined cadence.
- 05
Adjust
Protocols are refined over time. Guided care, not a kit in the mail.
How it is thought to work
The proposed mechanism runs through a pathway most readers will have met under another name. MOTS-c appears to act on the folate-methionine cycle, causing an intermediate to accumulate, which activates AMP-activated protein kinase (AMPK), the cell's energy sensor. When AMPK is switched on, cells shift toward using fuel rather than storing it.
That is the same pathway metformin is understood to act on by a different route, and the same one sustained exercise activates. A shared pathway is not an equivalence, but it is why MOTS-c draws so much interest.
Why people choose MOTS-c
People come to MOTS-c with metabolic goals. Here is what the research looks at for each, and how the program keeps track.
The human research is still catching up with the animal work, which is why your plan is anchored to measurements. The metabolic evidence goes through the underlying studies.
MOTS-c and exercise
In the laboratory, MOTS-c belongs to the research field of exercise mimetics: molecules that act on part of the pathway training activates. It is a useful research term, not a description of what MOTS-c does for a person.
Exercise changes cardiac output, capillary density, mitochondrial number, muscle, tendon and bone, insulin sensitivity, blood pressure, sleep, mood and balance. No single molecule covers that, so MOTS-c is for people already training: an addition to the work, not a substitute for it. MOTS-c and exercise is the long version.
What the program includes
Every MOTS-c prescription at ACT 2 comes with the same clinical structure:
Clinician-led assessment and prescription. A licensed clinician reviews your history, goals and current medications, and prescribes only when it is appropriate for you.
A licensed U.S. compounding pharmacy. Your prescription is prepared individually for you by a licensed U.S. compounding pharmacy.
Baseline labs and monitoring. A Comprehensive Lab Panel before you start, and the relevant markers rechecked as you go.
A published monthly price. What you pay is on the pricing page before you book, with no hidden consult charge.
Follow-up and adjustment. Your clinician reviews progress against the goals you agreed at the start and adjusts the plan, including when to pause or stop.
No membership fee. There is no fee to be assessed, and you pay for treatment only if it is prescribed and you choose to go ahead.
How it works at ACT 2
A compounded preparation, dispensed by a licensed pharmacy on an individual prescription. How it is taken is set by the prescribing clinician after a review.
Who it's for
Adults over 45 who are already working on their metabolic health, through training, nutrition and attention to their numbers, and want a clinician-led addition to the plan. Baseline labs come first, so there is something to measure against. See peptide therapy.
Start with your numbers
If MOTS-c caught your eye because of a fasting glucose that has been creeping, a waist that has changed or an HbA1c drifting upward, the program starts by measuring it properly: fasting insulin alongside glucose, HbA1c, a lipid panel including ApoB, liver enzymes, and body composition rather than weight alone. That is a baseline panel, and it gives you and your clinician something to measure against. A continuous glucose monitor can show how your own days actually run.
Your plan then builds on resistance training, protein, sleep and alcohol, with MOTS-c on top where it fits and, where it suits the person and the picture, a medication such as semaglutide. Peptide therapy covers how the category is handled here, and pricing is on the pricing page.
Clinicians who focus on longevity
Your visit is with a licensed clinician in your state. These are the members of the medical team whose practice centers on longevity; who you see depends on your state and availability.
Medical services are provided by licensed clinicians practicing through an independent professional entity.
Often considered alongside
Epithalon
CompoundedA peptide studied in telomere and cellular-aging research, prescribed within a clinician-led healthy-aging plan built on your own labs.
View treatmentNAD+ Injection
CompoundedA coenzyme central to cellular energy, explored to support energy and recovery in midlife.
View treatmentContinuous Glucose Monitor
Two weeks of real glucose data to set beside your labs, and an honest answer up front about whether you need it at all.
View treatmentProducts marked Compounded are prepared by a licensed compounding pharmacy under a prescription written for you. Compounded medications are not FDA-approved and are not equivalent to or interchangeable with any branded product.
MOTS-c, question by question
The specific questions people bring to this treatment, each answered on its own page and reviewed the same way this one is.
MOTS-c and Metabolism: The Evidence So Far
A mitochondrial-derived peptide studied for insulin sensitivity, mostly in cells and animals. What the research shows and where the human data stops.
ReadMOTS-c and Exercise: Why "Mimetic" Oversells It
MOTS-c is marketed as exercise in a bottle. Where the exercise-mimetic idea came from, what it gets wrong, and why nothing here replaces training.
Read
What the research shows
MOTS-c research sits mostly in cells and animals, where it has been studied for insulin sensitivity, metabolism and physical performance. Controlled human trials have not yet established a clinical benefit, and long-term safety in people has not been studied. It is not FDA-approved; it is prepared by a licensed compounding pharmacy under an individual prescription. On regulation: in April 2026 the FDA removed twelve peptide substances, MOTS-c among them, from Category 2 of its interim 503A bulk substances list after the nominations were withdrawn. That was not a safety finding, and it did not by itself authorize compounding. In July 2026 the FDA's Pharmacy Compounding Advisory Committee, which considered it in the context of obesity and osteoporosis, voted to recommend MOTS-c for the 503A Bulks List. Committee votes are advisory: formal addition to the list requires notice-and-comment rulemaking, which had not completed as of September 2026.
References
Government and professional-society sources consulted for this page.
- FDA Briefing Document for MOTS-c-Related Bulk Drug Substances, Pharmacy Compounding Advisory Committee, July 23-24, 2026 — U.S. Food and Drug Administration (2026)
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — U.S. Food and Drug Administration
- Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act — U.S. Food and Drug Administration
- FDA advisory committee nominates six peptides for pharmacies to compound — National Community Pharmacists Association (2026)
Frequently asked questions
That is a laboratory term for molecules that act on part of the pathway exercise activates. It describes the research field, not a replacement for training. MOTS-c and exercise explains the distinction.
Insulin sensitivity, cellular energy and metabolic regulation, mostly in cell and animal models. See the metabolic evidence.
It is encoded in mitochondrial DNA rather than the nuclear genome, which is unusual and is why it has drawn so much research interest.
Mostly observational. Plasma levels rise with exercise and vary with age, and a naturally occurring sequence variant has been associated with metabolic outcomes in some cohorts. An early-phase program using a MOTS-c analogue reached first-in-human testing and did not advance to large trials.
Both are understood to activate AMPK, by different routes. Metformin has decades of trials and outcome data; MOTS-c's research is mostly preclinical. It is a shared pathway, not an equivalent.
No. MOTS-c is prescribed to sit on top of training, not in place of it. Exercise does more for health than any single molecule, and your plan includes it.
Yes. A baseline gives you and your clinician something to measure against at follow-up.
No. The committee was weighing eligibility for pharmacy compounding, not effectiveness, and its recommendation takes effect only through rulemaking, which had not completed as of September 2026.
No. It is not FDA-approved for any use. It is prepared by a licensed compounding pharmacy under an individual prescription.
See if MOTS-c fits your plan
The right plan begins with knowing where you are. Start with a short eligibility check and a baseline — and we'll tell you, honestly, what fits.
We measure first. Then we act.
ACT 2 Health provides clinician-led care. Treatments described are available only to eligible patients following clinical evaluation and within applicable regulations. This page is educational and is not medical advice. Individual results vary.